Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ascelia Pharma AB ( (SE:ACE) ) has shared an update.
Ascelia Pharma announced that new clinical data on its manganese-based MRI contrast agent Orviglance has been accepted for an oral presentation at the European Society of Gastrointestinal and Abdominal Radiology congress in June 2026. The re-analysis of two Phase II trials shows Orviglance significantly improves detection of focal liver lesions versus unenhanced MRI, underscoring its potential as a safer alternative for patients at risk from gadolinium-based agents and supporting its regulatory push, including a filed U.S. New Drug Application with an anticipated FDA decision in mid-2026.
The most recent analyst rating on (SE:ACE) stock is a Hold with a SEK3.00 price target. To see the full list of analyst forecasts on Ascelia Pharma AB stock, see the SE:ACE Stock Forecast page.
More about Ascelia Pharma AB
Ascelia Pharma AB is a Swedish biotech company focused on orphan oncology treatments, developing and commercializing novel drugs for rare cancer-related conditions. Its pipeline includes Orviglance, an oral MRI contrast agent for detecting focal liver lesions in patients with reduced kidney function, and Oncoral, with the company listed on Nasdaq Stockholm and headquartered in Malmö.
Average Trading Volume: 807,586
Technical Sentiment Signal: Sell
Current Market Cap: SEK375.5M
For a thorough assessment of ACE stock, go to TipRanks’ Stock Analysis page.